Labcorp Holdings LH
NYSE · Services-Medical Laboratories · $30.1BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $13.1B | $11.9B | $12.2B | $13.0B | $14.0B | +7.2% | +1.5% | |
| Cost of Revenue (COGS) | $8.1B | $8.2B | $8.8B | $9.4B | $9.9B | +5.9% | +5.1% | |
| Gross Profit | $5.0B | $3.7B | $3.4B | $3.6B | $4.0B | +10.7% | −5.3% | |
| Selling, General & Admin (SG&A) | $1.7B | $1.8B | $2.0B | $2.2B | $2.2B | −0.6% | +7.0% | |
| Total Operating Expenses | $1.9B | $2.3B | $2.6B | $2.5B | $2.6B | +3.6% | +7.8% | |
| Operating Income (EBIT) | $3.0B | $1.4B | $725.6M | $1.1B | $1.4B | +27.4% | −17.9% | |
| Interest Expense | $211.8M | $179.8M | $199.6M | $208.3M | $224.1M | +7.6% | +1.4% | |
| Income Tax Expense | $690.0M | $233.9M | $188.5M | $212.4M | $229.8M | +8.2% | −24.0% | |
| GAAP Net Income | $2.4B | $1.3B | $418.0M | $746.0M | $877.0M | +17.6% | −22.1% | |
| Diluted EPS | $24.39 | $13.97 | $4.77 | $8.84 | $10.46 | +18.3% | −19.1% | |
| Diluted Shares | 97.5M | 91.6M | 87.6M | 84.4M | 83.8M | −0.7% | −3.7% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $1.4B | $430.0M | $536.8M | $1.5B | $532.3M | −65.0% | −21.2% | |
| Inventory | $401.4M | $470.6M | $474.6M | $493.2M | $534.7M | +8.4% | +7.4% | |
| Total Current Assets | $5.3B | $4.6B | $3.8B | $4.8B | $4.0B | −16.4% | −6.8% | |
| Total Assets | $20.4B | $20.2B | $16.7B | $18.4B | $18.4B | +0.1% | −2.5% | |
| Total Current Liabilities | $2.8B | $3.1B | $3.2B | $3.3B | $2.8B | −15.2% | +0.4% | |
| Total Debt (Short + Long Term) | $5.4B | $5.3B | $5.1B | $6.3B | $5.6B | −11.8% | +0.8% | |
| Total Liabilities | $10.1B | $10.0B | $8.8B | $10.3B | $9.8B | −5.4% | −0.8% | |
| Stockholders' Equity | $10.3B | $10.1B | $7.9B | $8.1B | $8.6B | +7.0% | −4.3% | |
| Net Cash / (Net Debt) | $-4.0B | $-4.9B | $-4.5B | $-4.8B | $-5.1B | −5.0% | — | |
| Invested Capital | $14.3B | $15.0B | $12.4B | $12.9B | $13.7B | +6.3% | −1.1% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $3.1B | $2.0B | $1.3B | $1.6B | $1.6B | +3.4% | −14.8% | |
| Depreciation & Amortization (D&A) | $577.0M | $537.2M | $577.3M | $643.5M | $681.1M | +5.8% | +4.2% | |
| Stock-Based Compensation (SBC) | $132.9M | $116.8M | $128.7M | $116.7M | $125.8M | +7.8% | −1.4% | |
| Capital Expenditures (CapEx) | $421.5M | $429.3M | $453.6M | $489.9M | $434.5M | −11.3% | +0.8% | |
| Free Cash Flow (FCF) | $2.7B | $1.5B | $874.1M | $1.1B | $1.2B | +10.0% | −18.2% | |
| True FCF (ex-SBC Owner Cash) | $2.6B | $1.4B | $745.4M | $979.2M | $1.1B | +10.3% | −19.4% | |
| Share Repurchases (Buybacks) | $1.7B | $1.1B | $1.0B | $250.1M | $450.0M | +79.9% | −27.9% | |
| Dividends Paid | — | $195.2M | $254.0M | $243.1M | $240.7M | −1.0% | +7.2% | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.